Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew B Frieman

Showing results (71-80 of 107) with videos related to

Pageof 11
Sort By:
Antimicrobial Agents and Chemotherapy|May 21, 2014
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infectionJulie Dyall, Christopher M Coleman, Brit J Hart, et al.
Biorxiv : the Preprint Server for Biology|June 30, 2021
Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infectionDavid C Schultz, Robert M Johnson, Kasirajan Ayyanathan, et al.
Communications Biology|August 12, 2022
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19James Logue, Arup R Chakraborty, Robert Johnson, et al.
Mbio|October 28, 2010
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signalingXinxia Peng, Lisa Gralinski, Christopher D Armour, et al.
Msystems|November 9, 2016
A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA VirusesLindsey A Moser, Lisbeth Ramirez-Carvajal, Vinita Puri, et al.
Nature Communications|October 6, 2023
Systematic functional interrogation of SARS-CoV-2 host factors using Perturb-seqSara Sunshine, Andreas S Puschnik, Joseph M Replogle, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialRaburn M Mallory, Neil Formica, Susan Pfeiffer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2015
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infectionKristen E Pascal, Christopher M Coleman, Alejandro O Mujica, et al.
Nature|February 7, 2022
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2David C Schultz, Robert M Johnson, Kasirajan Ayyanathan, et al.
Communications Biology|August 6, 2022
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variantEtsuro Nanishi, Marisa E McGrath, Timothy R O'Meara, et al.
Pageof 11

Showing results (71-80 of 107) with videos related to

Sort By:
Pageof 11
Antimicrobial Agents and Chemotherapy|May 21, 2014
Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infectionJulie Dyall, Christopher M Coleman, Brit J Hart, et al.
Biorxiv : the Preprint Server for Biology|June 30, 2021
Pyrimidine biosynthesis inhibitors synergize with nucleoside analogs to block SARS-CoV-2 infectionDavid C Schultz, Robert M Johnson, Kasirajan Ayyanathan, et al.
Communications Biology|August 12, 2022
PIKfyve-specific inhibitors restrict replication of multiple coronaviruses in vitro but not in a murine model of COVID-19James Logue, Arup R Chakraborty, Robert Johnson, et al.
Mbio|October 28, 2010
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signalingXinxia Peng, Lisa Gralinski, Christopher D Armour, et al.
Msystems|November 9, 2016
A Universal Next-Generation Sequencing Protocol To Generate Noninfectious Barcoded cDNA Libraries from High-Containment RNA VirusesLindsey A Moser, Lisbeth Ramirez-Carvajal, Vinita Puri, et al.
Nature Communications|October 6, 2023
Systematic functional interrogation of SARS-CoV-2 host factors using Perturb-seqSara Sunshine, Andreas S Puschnik, Joseph M Replogle, et al.
The Lancet. Infectious Diseases|August 13, 2022
Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trialRaburn M Mallory, Neil Formica, Susan Pfeiffer, et al.
Proceedings of the National Academy of Sciences of the United States of America|July 1, 2015
Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infectionKristen E Pascal, Christopher M Coleman, Alejandro O Mujica, et al.
Nature|February 7, 2022
Pyrimidine inhibitors synergize with nucleoside analogues to block SARS-CoV-2David C Schultz, Robert M Johnson, Kasirajan Ayyanathan, et al.
Communications Biology|August 6, 2022
mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variantEtsuro Nanishi, Marisa E McGrath, Timothy R O'Meara, et al.
Pageof 11